Evidence map›Paper›PMID 33725318›Full record

Trial reportInternational journal of hematology2021

Clinical features and chromosomal/genetic aberration in adult acute lymphoblastic leukemia in Japan: results of Fukuoka Blood & Marrow Transplant Group Studies ALL MRD 2002 and 2008.

Satoshi Morishige, Toshihiro Miyamoto, Tetsuya Eto, Naoyuki Uchida, Tomohiko Kamimura, Yasuhiko Miyazaki, Ryosuke Ogawa, Hirokazu Okumura, Tomoaki Fujisak, Hiromi Iwasaki and 9 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 15 institutions in 1 country.

Satoshi MorishigeDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Toshihiro MiyamotoDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Tetsuya EtoDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Naoyuki UchidaDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Tomohiko KamimuraDepartment of Hematology, HaraSanshin General Hospital, Fukuoka, Japan.
Yasuhiko MiyazakiDepartment of Hematology, Oita Prefectural Hospital, Oita, Japan.
Ryosuke OgawaDepartment of Hematology and Oncology, Japan Community Health Care Organization Kyushu Hospital, Kitakyushu, Japan.
Hirokazu OkumuraDepartment of Hematology, Toyama Prefectural Central Hospital, Toyama, Japan.
Tomoaki FujisakDepartment of Hematology, Matsuyama Red Cross Hospital, Matsuyama, Japan.
Hiromi IwasakiDepartment of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Noriaki KawanoDepartment of Hematology, Miyazaki Prefectural Hospital, Miyazaki, Japan.
Atsushi WakeDepartment of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan.
Takanori OhtaDepartment of Hematology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Yasushi TakamatsuDivision of Medical Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University Hospital, Fukuoka, Japan.
Toshiro KurokawaDepartment of Hematology, Toyama Red Cross Hospital, Toyama, Japan.
Yoshikiyo ItoDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.
Takahiro MaedaCenter for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Koji NagafujiDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan. knagafuji@med.kurume-u.ac.jp.ORCID http://orcid.org/0000-0003-4795-121X
Kurume University · JPKyushu University · JPToranomon Hospital · JPFukuoka University Hospital · JPHamanomachi Hospital · JPHarasanshin Hospital · JPImamura Hospital · JPKitakyushu Municipal Medical Center · JPKyushu Hospital · JPKyushu University Hospital · JPMatsuyama Red Cross Hospital · JPMiyazaki Prefectural Hospital · JPNational Kyushu Medical Center · JPOita Prefectural Hospital · JPToyama Prefectural Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute lymphoblastic leukemia (ALL) is a common neoplasm in children, but less frequent in adults. Since information on clinical features and genetics of adult ALL in Japan is limited, we analyzed 215 subjects aged 16-65 years with untreated ALL enrolled in the Fukuoka Blood & Marrow Transplant Group studies ALL MRD 2002 and 2008. The prevalence of ALL was bimodal, with the larger group aged 56-65 years. Immunophenotypic characterization showed B-lineage is more frequent than T-lineage ALL (78.6 vs 13.0%), with age-related differences. The proportion with BCR-ABL1 rearrangement increased progressively with age, up to 55.7% among subjects aged over 56-65 years. Rearrangements involving the KMT2A gene, ETV6-RUNX1, and TCF3-PBX1 were rare in this study cohort. The overall incidence of hyperdiploidy was only 1.7%, and there were no cases with hypodiploidy. Overall survival varied by age and cytogenetics. Older subjects and those with BCR-ABL1 tended to have inferior outcomes. In this epidemiological study of Japanese adult ALL, the majority of subjects had B-lineage ALL, the T-cell phenotype was most frequent in those aged 16-25, and BCR-ABL1 rearrangement was very common, with prevalence increasing with age. These types of adult ALL are potentially manageable with targeted therapies.

Indexed as

Chromosome AberrationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaAdolescentAdultAgedDisease-Free SurvivalFemaleFollow-Up StudiesHumansJapanMaleMiddle AgedNeoplasm ProteinsSurvival RateNeoplasm ProteinsAcute lymphoblastic leukemiaAdultBCR-ABL1Clinical featuresCytogenetics

Identifiers

PMID33725318
OpenAlexW3137549836

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.